HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

HUTCHMED announced that new and updated data from studies of compounds discovered by HUTCHMED will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2026. The presentations will include preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate (ATTC), and updated results from trials of surufatinib. HMPL-A580 demonstrated potent anti-tumor effects in preclinical models by inhibiting EGFR-expressing cancer cells. Surufatinib data will be presented from a Phase Ib/II trial in metastatic small bowel adenocarcinoma and appendiceal carcinoma, and an exploratory Phase II study in pancreatic ductal adenocarcinoma. The ATTC platform combines monoclonal antibodies with small-molecule inhibitor payloads for a dual mechanism of action, aiming for synergistic anti-tumor activity and improved safety profiles. Surufatinib, an oral angio-immuno kinase inhibitor, is marketed in China as SULANDA®. HUTCHMED is committed to discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.